glp-1 for ibs and This study reviews existing research on the use of receptor agonists in GLP-1s, Gut Motility & IBS

Tirzepatide dosing (FDA-approved schedule) Tirzepatide comes in pre-filled pens, eliminating the need for vial-and-syringe dosing

Tracking Hcy levels in lab tests can provide important information about a persons risk for diseases and overall health

(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)

Bojovi et al

Dietary fibre intake should be gradually increased to 30 grams daily, in line with UK recommendations